Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
查丹資本維持對Orchestra BioMed Hldgs的買入,維持20美元的目標股價
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Chardan Capital分析師Keay Nakae維持Orchestra BioMed Hldgs(納斯達克股票代碼:OBIO)的買入並維持20美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。